Fahad Alqahtani1, Sami Aljohani1, Khaled Boobes2, Elad Maor3, Assem Sherieh4, Charanjit S Rihal3, David R Holmes3, Mohamad Alkhouli5. 1. West Virginia University Heart & Vascular Institute, Morgantown. 2. Division of Nephrology, Department of Medicine, Northwestern University, Chicago, Ill. 3. Department of Cardiology, Mayo Clinic, Rochester, Minn. 4. Division of Nephrology, Department of Medicine, University of Michigan, Ann Arbor. 5. West Virginia University Heart & Vascular Institute, Morgantown; Department of Cardiology, Mayo Clinic, Rochester, Minn. Electronic address: Mohamad.Alkhouli@wvumedicine.org.
Abstract
BACKGROUND: The introduction of transcatheter aortic valve replacement (TAVR) expanded definitive therapy of aortic stenosis to many high-risk patients, but it has not been fully evaluated in the dialysis population. We aimed to evaluate the current trend and in-hospital outcome of surgical aortic valve replacement (SAVR) and TAVR in the dialysis population. METHODS: Severe aortic stenosis patients on maintenance dialysis who underwent SAVR or TAVR in the Nationwide Inpatient Sample database from January 1, 2005, through December 31, 2014, were included in our comparative analysis. The trends of SAVR and TAVR were assessed. In-hospital mortality, rates of major adverse events, hospital length of stay, cost of care, and intermediate care facility utilization were compared between the 2 groups using both unadjusted and propensity-matched data. RESULTS: Utilization of aortic valve replacement in dialysis patients increased 3-fold; a total of 2531 dialysis patients who underwent either SAVR (n = 2264) or TAVR (n = 267) between 2005 and 2014 were identified. Propensity score matching yielded 197 matched pairs. After matching, a 2-fold increase in in-hospital mortality was found with SAVR compared with TAVR (13.7% vs 6.1%, P = .021). Patients who underwent TAVR had more permanent pacemaker implantation (13.2% vs 5.6%, P = .012) but less blood transfusion (43.7% vs 56.8%, P = .02). Rates of other key morbidities were similar. Hospital length of stay (19 ± 16 vs 11 ± 11 days, P <.001) and non-home discharges (44.7% vs 31.5%, P = .002) were significantly higher with SAVR. Cost of hospitalization was 25% less with TAVR. CONCLUSION: In patients on maintenance dialysis, TAVR is associated with lower hospital mortality, resource utilization, and cost in comparison with SAVR.
BACKGROUND: The introduction of transcatheter aortic valve replacement (TAVR) expanded definitive therapy of aortic stenosis to many high-risk patients, but it has not been fully evaluated in the dialysis population. We aimed to evaluate the current trend and in-hospital outcome of surgical aortic valve replacement (SAVR) and TAVR in the dialysis population. METHODS:Severe aortic stenosispatients on maintenance dialysis who underwent SAVR or TAVR in the Nationwide Inpatient Sample database from January 1, 2005, through December 31, 2014, were included in our comparative analysis. The trends of SAVR and TAVR were assessed. In-hospital mortality, rates of major adverse events, hospital length of stay, cost of care, and intermediate care facility utilization were compared between the 2 groups using both unadjusted and propensity-matched data. RESULTS: Utilization of aortic valve replacement in dialysis patients increased 3-fold; a total of 2531 dialysis patients who underwent either SAVR (n = 2264) or TAVR (n = 267) between 2005 and 2014 were identified. Propensity score matching yielded 197 matched pairs. After matching, a 2-fold increase in in-hospital mortality was found with SAVR compared with TAVR (13.7% vs 6.1%, P = .021). Patients who underwent TAVR had more permanent pacemaker implantation (13.2% vs 5.6%, P = .012) but less blood transfusion (43.7% vs 56.8%, P = .02). Rates of other key morbidities were similar. Hospital length of stay (19 ± 16 vs 11 ± 11 days, P <.001) and non-home discharges (44.7% vs 31.5%, P = .002) were significantly higher with SAVR. Cost of hospitalization was 25% less with TAVR. CONCLUSION: In patients on maintenance dialysis, TAVR is associated with lower hospital mortality, resource utilization, and cost in comparison with SAVR.
Authors: Martin B Leon; Craig R Smith; Michael Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; David L Brown; Peter C Block; Robert A Guyton; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Pamela S Douglas; John L Petersen; Jodi J Akin; William N Anderson; Duolao Wang; Stuart Pocock Journal: N Engl J Med Date: 2010-09-22 Impact factor: 91.245
Authors: Dale M Kobrin; Fenton H McCarthy; Howard C Herrmann; Saif Anwaruddin; Sidney Kobrin; Wilson Y Szeto; Joseph E Bavaria; Peter W Groeneveld; Nimesh D Desai Journal: Ann Thorac Surg Date: 2015-08-11 Impact factor: 4.330
Authors: Sushrut S Waikar; Ron Wald; Glenn M Chertow; Gary C Curhan; Wolfgang C Winkelmayer; Orfeas Liangos; Marie-Anne Sosa; Bertrand L Jaber Journal: J Am Soc Nephrol Date: 2006-04-26 Impact factor: 10.121
Authors: Vinod H Thourani; Eric L Sarin; W Brent Keeling; Patrick D Kilgo; Robert A Guyton; Ameesh B Dara; John D Puskas; Edward P Chen; William A Cooper; J David Vega; Cullen D Morris; Omar M Lattouf Journal: Ann Thorac Surg Date: 2011-02-25 Impact factor: 4.330
Authors: Vinod H Thourani; W Brent Keeling; Eric L Sarin; Robert A Guyton; Patrick D Kilgo; Ameesh B Dara; John D Puskas; Edward P Chen; William A Cooper; J David Vega; Cullen D Morris; Michael E Halkos; Omar M Lattouf Journal: Ann Thorac Surg Date: 2011-05-04 Impact factor: 4.330
Authors: Matthew R Reynolds; Yang Lei; Kaijun Wang; Khaja Chinnakondepalli; Katherine A Vilain; Elizabeth A Magnuson; Benjamin Z Galper; Christopher U Meduri; Suzanne V Arnold; Suzanne J Baron; Michael J Reardon; David H Adams; Jeffrey J Popma; David J Cohen Journal: J Am Coll Cardiol Date: 2016-01-05 Impact factor: 24.094
Authors: Gloria Färber; Sabine Bleiziffer; Torsten Doenst; Dimitra Bon; Andreas Böning; Helge Weiler; Eva Herrmann; Christian Frerker; Andreas Beckmann; Helge Möllmann; Stephan Ensminger; Raffi Bekeredjian; Thomas Walther; Wolfgang Harringer; Hugo A Katus; Christian W Hamm; Friedhelm Beyersdorf; Timm Bauer; Stephan Fichtlscherer Journal: Clin Res Cardiol Date: 2020-09-23 Impact factor: 5.460
Authors: Alexander Lauten; Tanja K Rudolph; David Messika-Zeitoun; Jeetendra Thambyrajah; Antonio Serra; Eberhard Schulz; Norbert Frey; Jiri Maly; Marco Aiello; Guy Lloyd; Alessandro Santo Bortone; Alberto Clerici; Georg Delle-Karth; Johannes Rieber; Ciro Indolfi; Massimo Mancone; Loic Belle; Martin Arnold; Berto J Bouma; Matthias Lutz; Cornelia Deutsch; Jana Kurucova; Martin Thoenes; Peter Bramlage; Richard Paul Steeds Journal: Open Heart Date: 2021-01